文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种整合的多组学分析方法确定了非肌肉浸润性膀胱癌的预后分子亚型。

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.

机构信息

Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark.

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

出版信息

Nat Commun. 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w.


DOI:10.1038/s41467-021-22465-w
PMID:33863885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8052448/
Abstract

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an integrative multi-omics analysis of patients diagnosed with NMIBC (n = 834). Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provide independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirms the higher infiltration of class 2b tumors and demonstrates an association between higher immune cell infiltration and lower recurrence rates. Finally, the independent prognostic value of the transcriptomic classes is documented in 1228 validation samples using a single sample classification tool. The classifier provides a framework for biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.

摘要

非肌肉浸润性膀胱癌(NMIBC)的分子特征是具有不同临床结局的大生物学异质性。在这里,我们对诊断为 NMIBC 的患者(n=834)进行了综合的多组学分析。转录组分析确定了反映肿瘤生物学和疾病侵袭性的四个类别(1、2a、2b 和 3)。基于转录组的亚分型和染色体不稳定性水平提供了独立的预后价值,超过了既定的预后临床病理参数。高染色体不稳定性、p53 通路破坏和 APOBEC 相关突变与转录组 2a 类和不良预后显著相关。RNA 衍生的免疫细胞浸润与染色体不稳定的肿瘤相关,并在 2b 类中富集。空间蛋白质组学分析证实了 2b 类肿瘤的更高浸润程度,并表明更高的免疫细胞浸润与更低的复发率之间存在关联。最后,使用单个样本分类工具在 1228 个验证样本中证明了转录组类别的独立预后价值。该分类器为生物标志物的发现以及在下一代临床试验中优化治疗和监测提供了框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/bf6545a6bce4/41467_2021_22465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/fd2763d5bf22/41467_2021_22465_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/1b2c9e95622e/41467_2021_22465_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/74fe9e377af2/41467_2021_22465_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/5ffdba699e59/41467_2021_22465_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/bf6545a6bce4/41467_2021_22465_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/fd2763d5bf22/41467_2021_22465_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/1b2c9e95622e/41467_2021_22465_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/74fe9e377af2/41467_2021_22465_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/5ffdba699e59/41467_2021_22465_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fed1/8052448/b8a30413502a/41467_2021_22465_Fig6_HTML.jpg

相似文献

[1]
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.

Nat Commun. 2021-4-16

[2]
Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer.

Aging (Albany NY). 2020-6-24

[3]
Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.

J Cancer Res Ther. 2021

[4]
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

J Urol. 2017-5-6

[5]
HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.

J Urol. 2010-12-18

[6]
Bladder Tumor Subtype Commitment Occurs in Carcinoma Driven by Key Signaling Pathways Including ECM Remodeling.

Cancer Res. 2021-3-15

[7]
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.

Future Oncol. 2021-8

[8]
Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.

Urol Oncol. 2018-11-13

[9]
Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma.

J Cancer Res Ther. 2021-7

[10]
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.

Int Urol Nephrol. 2015-9

引用本文的文献

[1]
Expression of PD-1 and PD-L1 in BCG-treated NMIBC.

Bladder Cancer. 2025-8-17

[2]
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.

Nature. 2025-8-20

[3]
A Double-Humanized Murine Model in Bladder Cancer: A Novel Preclinical Model for Cancer Immunology Research.

Cancer Med. 2025-8

[4]
A technical review of multi-omics data integration methods: from classical statistical to deep generative approaches.

Brief Bioinform. 2025-7-2

[5]
Machine Learning and Experimental Validation Reveal MYH11 as a Novel Prognostic Biomarker and Therapeutic Target in Bladder Cancer.

J Inflamm Res. 2025-6-25

[6]
Retinoic acid metabolism related gene CYP26B1 promotes tumor stemness and tumor microenvironment remodeling in bladder cancer.

J Cancer. 2025-4-22

[7]
Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.

J Transl Med. 2025-6-17

[8]
Deciphering riddles in molecular subtyping of bladder cancer.

Asian J Urol. 2025-4

[9]
Impact of concomitant carcinoma in situ distribution on non-muscle-invasive bladder cancer progression risk.

BJU Int. 2025-8

[10]
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.

Elife. 2025-5-23

本文引用的文献

[1]
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.

Nat Commun. 2020-9-25

[2]
Identification of Differential Tumor Subtypes of T1 Bladder Cancer.

Eur Urol. 2020-10

[3]
Identification of an immunotherapy-responsive molecular subtype of bladder cancer.

EBioMedicine. 2019-11-15

[4]
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Clin Cancer Res. 2019-11-11

[5]
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma.

Int J Cancer. 2019-11-14

[6]
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Eur Urol. 2020-4

[7]
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

Eur Urol. 2019-8-20

[8]
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Sci Transl Med. 2019-7-31

[9]
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.

Nat Commun. 2019-7-5

[10]
Molecular pathology of the luminal class of urothelial tumors.

J Pathol. 2019-8-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索